We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and the epidemic in NonAlcoholic SteatoHepatitis (NASH). A Phase 2 study of seladelpar demonstrated clinical activity and established proof-of-concept in PBC. We have initiated the seladelpar Phase 3 registration study for the treatment of PBC. Seladelpar has received an orphan designation from the U.S. Food and Drug Administration and the PRIority MEdicine (PRIME) status from the European Medicines Agency. We are also conducting a Phase 2b proof-of-concept study of seladelpar for the treatment of NASH.
7575 Gateway Blvd
Newark, CA 94560 US